WO2000061597A9 - Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin - Google Patents
Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolinInfo
- Publication number
- WO2000061597A9 WO2000061597A9 PCT/US2000/009311 US0009311W WO0061597A9 WO 2000061597 A9 WO2000061597 A9 WO 2000061597A9 US 0009311 W US0009311 W US 0009311W WO 0061597 A9 WO0061597 A9 WO 0061597A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ohgonucleotide
- nucleolin
- rich
- binding
- oligonucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 129
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 102100021010 Nucleolin Human genes 0.000 title claims abstract description 108
- 108010044762 nucleolin Proteins 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000001028 anti-proliverative effect Effects 0.000 title claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 74
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims abstract description 37
- 230000003211 malignant effect Effects 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims abstract description 16
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940029575 guanosine Drugs 0.000 claims abstract description 16
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 147
- 238000009739 binding Methods 0.000 claims description 65
- 230000027455 binding Effects 0.000 claims description 63
- 239000000284 extract Substances 0.000 claims description 40
- 102000014914 Carrier Proteins Human genes 0.000 claims description 23
- 108091008324 binding proteins Proteins 0.000 claims description 23
- 238000002337 electrophoretic mobility shift assay Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 12
- 229960004316 cisplatin Drugs 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001948 caffeine Drugs 0.000 claims description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 125000006308 propyl amino group Chemical group 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- 229960003171 plicamycin Drugs 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 8
- 206010020718 hyperplasia Diseases 0.000 abstract description 3
- 230000002390 hyperplastic effect Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 64
- 230000000694 effects Effects 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 19
- 206010060862 Prostate cancer Diseases 0.000 description 17
- 238000000134 MTT assay Methods 0.000 description 16
- 231100000002 MTT assay Toxicity 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 230000009422 growth inhibiting effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- 229960002897 heparin Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- -1 5-Fluorouracil Nucleoside Chemical class 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 238000001899 southwestern blot Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 108091035539 telomere Proteins 0.000 description 8
- 102000055501 telomere Human genes 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000007999 Nuclear Proteins Human genes 0.000 description 7
- 108010089610 Nuclear Proteins Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 239000003560 cancer drug Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000012623 DNA damaging agent Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 108700015690 Immunoglobulin Switch Region Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000005679 Peltier effect Effects 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101000890936 Rattus norvegicus Type-1B angiotensin II receptor Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101100345673 Xenopus laevis mix-b gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003003 empirical scoring function Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000028706 ribosome biogenesis Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- the present invention relates to inhibiting cell proliferation. Specifically, the present invention relates to specific oligonucleotides which inhibit cell proliferation, including that of neoplastic and/or dysplastic cells, by binding to specific proteins associated with cell proliferation.
- Oligonucleotides have the potential to recognize unique sequences of
- RNA or RNA DNA or RNA with a remarkable degree of specificity. For this reason they have been considered as promising candidates to realize gene specific therapies for the treatment of malignant, viral and inflammatory diseases.
- Two major strategies of oligonucleotide-mediated therapeutic intervention have been developed, namely, the antisense and antigene approaches.
- the antisense strategy aims to down-regulate expression of a specific gene by hybridization of the ohgonucleotide to the specific mRNA, resulting in inhibition of translation.
- Gewirtz et al. (1998) Blood 92, 712-736; Crooke (1998) Antisense
- the antigene strategy proposes to inhibit transcription of a target gene by means of triple helix formation between the ohgonucleotide and specific sequences in the double-stranded genomic DNA.
- Helene et al. (1997) Ciba Found. Symp. 209, 94-102.
- Clinical trials based on the antisense approach are now showing that oligonucleotides can be administered in a clinically relevant way and have few toxic side effects.
- Gewirtz et al. (1998) Blood 92, 712-736; Agrawal et al. (1998) Antisense Nucleic Acid Drug Dev. 8, 135-139.
- phosphodiester and phosphorothioate oligodeoxynucleotides containing contiguous guanosines (G) have been repeatedly found to have non-antisense effects on the growth of cells in culture.
- Oligonucleotides are polyanionic species that are internalized in cells, probably by receptor-mediated endocytosis. Nlassov et al. (1994) Biochim. Biophys. Acta 1197, 95-108. They are likely to interact with many biomolecules within the cell and also in the extracellular membrane by virtue of both their charge and their shape, as well as sequence-specific interactions. The proteins that bind to oligonucleotides and mediate non-antisense effects have not yet been unequivocally identified.
- the present application identifies a G-rich ohgonucleotide binding protein, and the ability of a G-rich ohgonucleotide to bind to this protein is correlated with its propensity to form G-quartets, and with its ability to inhibit the growth of tumor cells .
- GROs G-rich oligonucleotides
- Applicants have described G-rich oligonucleotides (GROs) that have potent growth inhibitory effects that are unrelated to any expected antisense or antigene activity. While the mechanism of these effects has not yet been specifically delineated, Applicants have demonstrated that the antiproliferative effects of these oligonucleotides are related to their ability to bind to a specific cellular protein. Because the GRO binding protein is also recognized by anti- nucleolin antibodies, Applicants have concluded that this protein is either nucleolin itself, or a protein of a similar size that shares immunogenic similarities with nucleolin.
- Nucleolin is an abundant multifunctional 110 kDa phosphoprotein thought to be located predominantly in the nucleolus of proliferating cells (for reviews, see Tuteja et al. (1998) Crit. Rev. Biochem. Mol. Biol. 33, 407-436; Ginisty et al. (1999) J. Cell Sci. 112, 761-772). Nucleolin has been implicated in many aspects of ribosome biogenesis including the control of rDNA transcription, pre-ribosome packaging and organization of nucleolar chromatin. Tuteja et al. (1998) Crit. Rev. Biochem. Mol. Biol. 33, 407-436; Ginisty et al. (1999) J. Cell Sci. 112, 761-772; Ginisty et al. (1998) EMBO J. 17, 1476-1486. Another emerging role for nucleolin is as a shuttle protein that transports viral and cellular proteins between the cytoplasm and nucleus/nucleolus of the cell.
- Nucleolin is also implicated, directly or indirectly, in other roles including nuclear matrix structure (Gotzmann et al. (1997) Electrophoresis 18, 2645- 2653), cytokinesis and nuclear division (Leger-Silvestre et al. (1997)
- nucleolin Chromosoma 105, 542-52), and as an RNA and DNA helicase (Tuteja et al. (1995) Gene 160, 143-148).
- the multifunctional nature of nucleolin is reflected in its multidomain structure consisting of a histone-like N-terminus, a central domain containing RNA recognition motifs, and a glycine/arginine rich C-terminus. Lapeyre et al. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 1472-1476.
- nucleolin levels of nucleolin are known to relate to the rate of cellular proliferation (Derenzini et al. (1995) Lab. Invest. 73, 497-502; Roussel et al. (1994) Exp. Cell Res. 214, 465-472.), being elevated in rapidly proliferating cells, such as malignant cells, and lower in more slowly dividing cells. For this reason, nucleolin is an attractive therapeutic target.
- Applicants have identified an ohgonucleotide binding protein and shown a correlation between binding to this protein and antiproliferative activity for a series of G-rich oligonucleotides.
- nucleolin binding and antiproliferative activity for other, non-G-rich, oligonucleotides has not yet been fully evaluated.
- MIX1 mixed sequence ohgonucleotide
- Nucleolin contains RNA binding domains that can recognize specific sequences of RNA or single- stranded DNA.
- nucleolin binds to G-rich oligonucleotides
- nucleolin can bind to other G-quartet forming sequences, such as immunoglobulin switch regions and ribosomal gene sequences (Dempsey et al. (1999) J. Biol. Chem. 274, 1066-1071 and Hanakai et al. (1999) J. Biol. Chem. 274, 15903-15912). It is possible that nucleolin has currently undefined functions in vivo that depend on recognition of G-rich sequences in, for example, ribosomal DNA switch region sequences or telomeres.
- nucleolin is one of the nuclear organizer region (NOR) proteins whose levels, as measured by silver staining, are assessed by pathologists as a marker of cell proliferation and an indicator of malignancy. Nucleolm is thus a tumor-selective target for therapeutic intervention, and strategies to reduce the levels of functional nucleolin are expected to inhibit tumor cell growth.
- NOR nuclear organizer region
- nucleolin inhibition on the growth of cells have not been well studied, but inhibition of a protein whose functions include ribosome production, nuclear transport and cell entry should have profound effects on the growth of cells.
- the present invention provides a method for inhibiting the proliferation of malignant, dysplastic, and/or hyperproliferative cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich ohgonucleotide.
- the present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is implicated in the proliferation of cells, specifically malignant, dysplastic, and/or hyperproliferative cells.
- the present invention also provides methods of screening for molecules or compounds capable of binding to G-rich ohgonucleotide binding proteins.
- Figure 1 MTT assays showing the growth of tumor cells treated with G-rich oligonucleotides or water as a control over time, wherein (A) the cell type is DU145, (B) the cell type is MDA-MB-231, (C) the cell type is HeLa,
- GRO29A GRO29A
- ⁇ GRO26A ⁇ GRO26A
- EB water EB water
- Figure 2 illustrates the results of MTT assays showing the growth of (A) DU145 cells, (B) MDA-MB-231 cells, and (C) HS27 cells treated with GRO29A active ohgonucleotide (closed squares), GRO15B (inactive ohgonucleotide, half-filled squares), or no ohgonucleotide (open squares).
- Figure 3 MTT assays showing the dose dependence of growth inhibition by GRO29A for leukemic cell lines, U937 and K563, and a non- malignant mouse hematopoietic stem cell line (ATCC 2037).
- Figure 4 are UN. thermal renaturation curves to assess G-quartet formation by G-rich oligonucleotides wherein (A) TEL, (B) GRO29A, (C) GRO15A, (D) GRO15G, and (E) GRO26A.
- Figure 5 is a chromatogram illustrating uptake of G-rich ohgonucleotide by MDA-MB-231 breast cancer cells.
- FIG. 6 (A) Electrophoretic mobility shift assay (EMS A) showing binding of 32 P-labeled oligonucleotides to 5 ⁇ g HeLa nuclear extracts and competition by unlabeled competitor oligonucleotides (100-fold molar excess over labeled ohgonucleotide). Competitor oligonucleotides are abbreviated to T (TEL), 29 (GRO29A), 26 (GRO26A) and 15A (GRO15A).
- TEL Electrophoretic mobility shift assay
- FIG. 7 (A) is a chromatogram illustrating an MTT assay of MDA- MB-231 cells treated with a single 10 ⁇ M dose of G-rich ohgonucleotide or
- (B) illustrates an EMSA showing complex formed by binding of 5 ⁇ g of MDA-MB-231 nuclear extracts to 32 P-labeled TEL ohgonucleotide and competition by unlabeled G-rich oligonucleotides (10-fold molar excess);
- (C) is a chromatogram illustrating the results of a MTT assay of MDA-MB-231 cells treated with a single 10 ⁇ M dose of 3 '-protected C-rich ohgonucleotide (CRO) or mixed sequence ohgonucleotide (MIX1) or with 20 units/ml heparin (HEP), in comparison with inactive (GRO15B) and active (GRO29A) G-rich oligonucleotides wherein the assay was performed on day 7; and (D) is a chromatogram illustrating the results of an MTT as
- Figure 8 (Top) Southwestern blot using radiolabeled GRO15A to detect GRO binding protein in nuclear (N) and cytoplasmic (C) extracts from various cell lines. (Bottom): Sensitivity of various cell lines to the growth inhibitory effects of GRO29A and GRO 15 A.
- FIG. 9 (A) Southeastern (SW) and Western (W) blots probed respectively with 32 P-labeled active G-rich ohgonucleotide (GRO15A) or nucleolin antiserum. Left panel shows MDA-MB-231 nuclear extracts (5 ⁇ g/lane); right panel shows HeLa nuclear extracts (Promega Inc., 5 ⁇ g/lane).
- FIG 10 illustrates the results of immunofluoresence studies showing anti-nucleolin staining of MDA-MB-231 cells untreated (A) and treated (B) with GRO29A 72 hours after treatment.
- Figure 11 Staining of non-permeabilized DU145 cells with nucleolin antibody, showing the presence of nucleolin in the plasma membrane.
- Figure 12 (A) G-quartet, illustrating hydrogen bonding interaction. (B) Molecular model of GRO29A, showing a proposed dimeric structure stabilized by 8 G-quartets. (C) Dimethyl sulfate footprinting of GRO29A, showing preferential methylation of the loop region guanosine, consistent with the predicted model.
- Figure 13 (A) MTT assay showing antiproliferative activity of novel guanosine-rich oligonucleotides against MDA-MB-231 breast cancer cells. (B)
- Figure 14 A photograph depicting the results of an electrophoretic mobility shift assay for screening nucleolin-binding compounds wherein:
- Taxol Natural product cancer drug; anti-mitotic modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier modifier
- the present invention provides novel guanine rich oligonucleotides (GROs) and methods of using at least one GRO to inhibit the growth of neoplastic, dysplastic, or otherwise hyperproliferative cells in a subject.
- GROs novel guanine rich oligonucleotides
- Examples of the novel oligonucleotides of the present invention have the following nucleotide sequences and are designated GRO14A (5'-
- GRO28A (5 '-TTTGGTGGTGGTGGTTGTGG
- GGTGGTGGTGG-3' SEQ ID No: 10 GRO14C (5'-GGTGGTTGTGGTGG- 3' SEQ ID No: 11), GRO26B (5'-GGTGGTGGTGGTTGTGGTGG TGGTGG-3' SEQ ID No: 12), GR056A (5'-GGTGGTGGTGGTTG
- GRO32B 5'-TTTGGTGGTGGTGGTTGTGGT
- GGTGGTGGTTT-3 ' SEQ ID No: 15
- GR029-6 5 '-GGTGGTGGTGGTTGT
- GRO15C, GRO28H and GRO24I have been shown to inhibit the growth of breast cancer cells and/or to compete for binding to the G-rich ohgonucleotide binding protein as shown by an electrophoretic mobility shift assay (see Figures 6 and 7).
- Demonstration of activity and protein binding of GROs of the present invention include GRO 15 A, 29 A are shown in Figure 1 and Figure
- GRO14A, 25A, 28A are shown in Figure 7; GRO11A, 14C, 26B, 32A, 56A are shown in Figure 3; GRO29-2, 29-3, 29-5, 29-6, 28B have also been shown to have antiproliferative activity and protein binding.
- G-rich ohgonucleotide it is meant that the oligonucleotides consist of 4-100 nucleotides (preferably 10-30 nucleotides) with DNA, RNA,
- oligonucleotides have antiproliferative activity against cells and bind to GRO binding protein and/or nucleolin. These properties can be demonstrated using the MTT assay and the EMSA technique shown in Figure 6B, or other similar assays.
- the oligonucleotides of the present invention are rich in guanosine and are capable of forming G-quartet structures. Specifically, the oligonucleotides of the present invention are primarily comprised of thymidine and guanosine with at least one contiguous guanosine repeat in the sequence of each ohgonucleotide.
- the G-rich oligonucleotides are stable and can remain undegraded in serum for prolonged periods of time and have been found to retain their growth inhibiting effects for periods of at least seven days.
- the term "ohgonucleotide” is defined as a molecule comprising two or more deoxyribonucleotides or ribonucleotides.
- nucleolin and nucleolin-like proteins The exact size depends on a number of factors including the specificity and binding affinity to target ligands.
- bases or “nucleotides,” the terms include both deoxyribonucleic acids and ribonucleic acids.
- the novel oligonucleotides of the present invention can be used to inhibit the proliferation of malignant, dysplastic and/or hyperproliferative cells by specifically binding to specific cellular proteins associated with cell proliferation including nucleolin and nucleolin-like proteins.
- nucleolin-like is used to define a protein that is either nucleolin itself or a protein of similar size that shares immunogenic similarities and/or functional similarities with nucleolin.
- the oligonucleotides can be modified at their 3 ' end in order to alter a specific property of the ohgonucleotide.
- the 3 '-terminus of the ohgonucleotide can be modified by the addition of a propylamine group which has been found to increase the stability of the ohgonucleotide to serum nucleases.
- Other modifications that are well known in the art include 3 ' and
- inhibitortion of the proliferation of malignant, dysplastic, and or hyperplastic cells includes any partial or total growth inhibition and includes decreases in the rate of proliferation or growth of the cells.
- neoplastic includes the new, abnormal growth of tissues and/or cells, such as a cancer or tumor, including, for example, breast cancer, leukemia or prostate cancer.
- neoplastic also includes malignant cells which can invade and destroy adjacent structures and/or metastasize.
- displastic includes any abnormal growth of cells, tissues, or structures including conditions such as psoriasis.
- subject means all animals including humans. Examples of subjects include humans, cows, dogs, cats, goats, sheep, and pigs.
- Those skilled in the art are easily able to identify patients having a malignant, dysplastic, or a hyperproliferative condition such as a cancer or psoriasis, respectively.
- patients who have a cancer such as breast cancer, prostate cancer, cervical carcinomas, and the like.
- a therapeutically effective amount is an amount of an ohgonucleotide of the present invention, that when administered to the subject, ameliorates a symptom of the disease, disorder, or condition, such as by inhibiting or reducing the proliferation of dysplastic, hyperproliferative, or malignant cells.
- the GROs of the present invention can be administered to a patient or subject either alone or as part of a pharmaceutical composition.
- the GROs can be administered to patients either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitonally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
- compositions of the GROs of the present invention suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound in such solid dosage forms, the active compound
- (GRO) is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
- fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
- binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
- humectants as for example, glycerol
- disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
- absorption accelerators as for example, quaternary ammonium compounds
- wetting agents as for example, cetyl alcohol, and glycerol monostearate
- adsorbent such as sodium citrate or dicalcium phosphate
- fillers or extenders as for example, starches, lactose,
- the dosage forms may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro- encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3- butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tefrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
- inert diluents commonly used in the art, such as water or other solvents, solub
- compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
- Dosage forms for topical administration of a GRO of this invention include ointments, powders, sprays, and inhalants.
- the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required.
- Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
- the GROs of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
- the GROs of the present invention can be administered to a patient at dosage levels in the range of about 1.5 mg to about 150 mg per day.
- a dosage in the range of about 0.2 mg to about 2.0 mg per kilogram of body weight per day is preferable.
- the specific dosage used can vary.
- the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
- the GROs of the present invention can be given in single and/or multiple dosages.
- the present invention cover GROs made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as through metabolism.
- the G-rich oligonucleotides of the present invention may also be used in combination with other chemotherapeutic agents to provide a synergistic or enhanced efficacy or inhibition of neoplastic cell growth.
- the G- rich oligonucleotides of the present invention can be administered in combination with chemotherapeutic agents including, for example, cis-platin, mitoxantrone, etoposide, camptothecin, 5-fluorouracil, vinblastine, paclitaxel, docetaxel, mithramycin A, dexamethasone, caffeine, and other chemotherapeutic agents well known to those skilled in the art.
- GRO29A acts synergistically with cis- platin in inhibiting MDA-MB-231 cell growth in vitro.
- the present invention provides a method for selecting oligonucleotides that bind to G-rich ohgonucleotide binding proteins.
- the method utilizes an electrophoretic mobility shift assay (EMSA), as described below, to screen for oligonucleotides that bind strongly to the specific protein and which, therefore, would be expected, according to the present invention, to have antiproliferative activity.
- Oligonucleotides to be screened as potential antiproliferative agents are labeled and then incubated with nuclear extracts in the absence or presence of unlabeled competitor ohgonucleotide and are allowed to react.
- the reaction mixtures are then electrophoresed and mobility shifts and/or bond intensity can be used to identify those oligonucleotides which have bound to the specific protein.
- unlabeled compounds to be screened are incubated with nuclear extracts in the presence of labeled ohgonucleotide (for example 5'- TTAGGGTTAGGG TTAGGG TTAGGG) and binding is assessed by a decrease in the intensity of the shifted band, as in Figure 6B.
- labeled ohgonucleotide for example 5'- TTAGGGTTAGGG TTAGGG TTAGGG TTAGGG
- compounds to be screened can be added to cells growing in culture.
- Potential antiproliferative agents will be identified as those which cause an altered intensity and localization of nucleolin, as detected by immuno fluorescence microscopy, as shown in Figure 10.
- Oligonucleotides 3 '-modified oligonucleotides were purchased from Oligos Etc. (Wilsonville, OR) or synthesized at the University of Alabama at Birmingham using 3'-C3-amine CPG columns from Glen Research (Sterling, NA). Unmodified oligonucleotides were obtained from Life Technologies, Inc., Gaithersburg, MD. Oligonucleotides were resuspended in water, precipitated in n-butyl alcohol, washed with 70% ethanol, dried and resuspended in sterile water or phosphate buffered saline (PBS). They were then sterilized by filtration through a 0.2 ⁇ m filter. Each ohgonucleotide was checked for integrity by 5'-radiolabeling followed by polyacrylamide gel
- Cell growth assays Cells were plated at low density (10 2 to 10 3 cells per well, depending on cell line) in the appropriate serum-supplemented medium in 96-well plates (one plate per MTT assay time point) and grown under standard conditions of cell culture. The following day (day 1) ohgonucleotide, or water as control, was added to the culture medium to give a final concentration of 15 ⁇ M. Further ohgonucleotide, equivalent to half the initial dose, was added to the culture medium on days two, three and four.
- MDA-MB-231 breast cancer cells (5 x 10 2 cells per well) were plated in a 96-well plate. After twenty-four hours, a single dose of ohgonucleotide, or equal volume of PBS as a control, was added to the culture medium to a final concentration of 10 ⁇ M. Viable cells were assessed seven days after plating using the MTT assay. For the experiment using 3 '-unmodified oligonucleotides (Fig. 7D), serum-supplemented medium
- serum-free medium containing ohgonucleotide (or serum-free medium alone in control wells). After incubation at 37°C for four hours, fetal calf serum (Life Technologies, Inc.) was added to the medium to give 10% v/v.
- Peltier effect heated cuvette holder and temperature controller (Amersham Pharmacia Biotech). Absorbance at 295 nm was monitored over a temperature range of 25-95 or 20-90°C at a heating/cooling rate of 0.5°C/min.
- MDA-MB-231 cells were seeded in twenty- four well plates at a density of 5xl0 5 cells/well. After twenty-four hours, ohgonucleotide (5 nmol of unlabeled ohgonucleotide and 5x10 6 cpm (approximately 1 pmol) of 5'- 32 P-labeled ohgonucleotide) was added directly to the culture medium to give a final concentration of 10 ⁇ M. Cells were incubated at 37°C for ten or twenty-six hours and were then washed three times with PBS. Cells were removed from the plate by trypsinization, washed, and collected in 100 ⁇ l of PBS.
- a 50- ⁇ l aliquot was counted by scintillation counting to assess cell-associated radioactivity. To ensure that the washing procedures were sufficient to remove all excess ohgonucleotide, the final PBS wash was counted and found to be very low compared with the cell-associated radioactivity. The remaining 50- ⁇ l aliquots were boiled for five minutes and placed on ice. An equal volume of phenol/chloroform was added, and the oligonucleotides were extracted in the aqueous phase, precipitated with n-butyl alcohol, and analyzed by denaturing polyacrylamide gel electrophoresis on a 15% gel.
- Electrophoretic mobility shift assays (EMSAs). Oligonucleotides were 5 '-labeled with 32 P using T4 kinase. Labeled ohgonucleotide (final
- HEPES binding buffer 25 mM HEPES pH 7.9, 4 mM KCl, 3mM MgCl 2 .
- NDM non-fat dried milk
- Hybridization was labeled ohgonucleotide (1-4 x 10 6 cpm) took place for two hours at 4°C in HEPES binding buffer supplemented with 0.25% NDM, 0.05%
- binding buffer and visualized by autoradiography.
- Western Blotting Western Blotting was carried out at room temperature in PBS buffer containing Tween 20 at 0.1% (for polyclonal antibody) or 0.05% (monoclonal antibody). PVDF membranes were blocked with PBS-Tween 20 containing 5% NDM for one hour, washed and incubated for one hour with a 1:1000 dilution of nucleolin antiserum or nucleolin monoclonal antibody (MBL Ltd., Japan, 1 ⁇ g/ml final concentration) in PBS- Tween 20.
- MBL Ltd. nucleolin antiserum or nucleolin monoclonal antibody
- oligonucleotides were added to the culture medium at a final concentration of 5 ⁇ M. After incubation for two hours at 37°C, cells were washed extensively
- lysis buffer 50 mM Tris.HCl pH 8.0, 150 mM NaCl, 0.02% (w/v) sodium azide, 0.1 mg/ml phenylmethyl sulfonyl fluoride, 1% (v/v) Nonidet P40, 0.5% (w/v) sodium deoxycholate, 0.5 mM dithiothreitol, 1 ⁇ g/ml aprotinin) followed by incubation at -20 °C for ten
- Genomic DNA was sheared by repeated injection of the lysate through a fine gauge needle. Lysate was added to streptavidin coated magnetic beads (MagneSphere, Promega Inc.) and incubated ten minutes at room temperature. Beads were captured and unbound sample was removed. Beads were then washed twice with 1 ml of lysis buffer and again with 1 ml of Buffer A. Finally, proteins were eluted by addition of 50 ⁇ l of loading buffer (containing 1% SDS and 5% 2-mercaptoethanol) and incubation for fifteen minutes at 65° C.
- HeLa nuclear extracts used in EMSAs were purchased from Promega Inc. (bandshift grade). Nuclear and cytoplasmic extracts from MDA- MB-231 cells were prepared using the protocol described in F.M. Ausubel et al. Ausubel et al. (Eds.) (1996) Current Protocols in Molecular Biology, Wiley, NY, Section 12.1. Plasma membrane proteins were prepared from MDA-MB- 231 cells using a method previously described. Yao et al. (1996) Biochemical Pharmacology 51, 431-436; Naito et al. (1988) J. Biol. Chem. 263, 11887- 11891. India Ink Staining. The membrane was incubated for 15 minutes at room temperature in PBS-Tween 20 containing three drops of Higgins India Ink 4415 and washed with distilled water.
- nucleolin Binding Assay To determine which non-oligonucleotide- based molecules or compounds are capable of binding to nucleolin, an EMSA was performed as described below and the results of which are shown in
- Figure 14 In this assay, the binding ability of several different molecules or compounds for nucleolin was examined. This type of assay can be utilized to screen for molecules or compounds capable of binding nucleolin.
- Cisplatin in 1% DMSO solution to give a final concentration of 0.5 ⁇ g/ml was added to the medium of MDA-MB-231 breast cancer cells growing in culture. After two hours, GRO29A (in PBS solution to give a final concentration of 8 ⁇ M) was added to the medium. After six days, the relative number of viable cells was determined using the MTT assay. Cells treated with GRO29A alone received an appropriate volume of 1% DMSO in place of cisplatin. Cells treated with cisplatin alone received an appropriate volume of PBS in place of GRO29A.
- the primary objective is to demonstrate in vivo efficacy of GROs against prostate cancer, and success in these studies may lead to clinical trials of GROs.
- the second objective is to examine nucleolin levels and characteristics in prostate cells. Nucleolin, a nucleolar protein involved in multiple aspects of cell growth, has been identified as the putative target for GRO effects. It is Applicants' hypothesis that GROs bind to and inactivate nucleolin. It is known that levels of nucleolin (in the nucleus) are positively correlated with the rate of cell proliferation, and thus, strategies that inhibit nucleolin have significant therapeutic potential. Applicants have shown that nucleolin is also present on the surface of prostate cancer cells, and this may be relevant to the mechanism of GRO effects.
- nucleolin may be elevated in malignant cells compared to normal cells. This would have implications in terms of nucleolin as a tumor cell marker.
- Another objective is to explore novel therapies for prostate cancer, such as combination therapies of GRO and chemotherapy agents, and small molecule inhibitors of nucleolin. Determining the activity of GROs in a series of cell lines derived from normal and malignant prostate tissue. Nucleolin levels in the nucleus, cytoplasm and plasma membrane of these cells will be examined using blotting techniques and immunofluorescence microscopy. To optimize delivery of GROs, uptake and activity of GROs introduced to cultured cells by a number of different methods can be studied.
- GROs are synergistic with some chemotherapy drugs. Therefore, the effects of combinations of GROs with a variety of cytotoxic and other agents in cultured cells can be examined, and tested for any synergistic combinations in animal models.
- a homology model of nucleolin based on the reported structures of many similar proteins can be constructed and used to identify potential small molecule inhibitors of nucleolin by a "virtual screening" method.
- the GROs of the present invention are potentially tumor-specific agents that are highly active against prostate cancer cells. They have a novel mechanism of action and enormous therapeutic potential in the fight against prostate cancer. Applicants have also identified nucleolin as a new target for therapeutic intervention in prostate cancer. Development of the understanding of this protein can lead to improved diagnostic or prognostic techniques for prostate cancer, or a new class of drugs that inhibit nucleolin.
- GRO29A ohgonucleotide
- PC-3 non-malignant (PZ-HPV-7 and rat YPEN-1), and multidrug resistant (rat AT3 BI and MLLB-2) cell lines.
- Cell lines can be purchased from ATCC.
- To determine nucleolin levels nuclear, cytoplasmic and plasma membrane extracts are prepared from each cell line by standard methods. Bates et al. (1999) J. Biol. Chem. 274(37):26369-77. Extracts are electrophoresed on 8% polyacrylamide-SDS gels and transferred to PVDF membranes. They are examined by Southwestern blotting (with radiolabeled GRO) and Western blotting (with nucleolin monoclonal antibody, Santa Cruz) to determine levels of GRO-binding protein/nucleolin. Cells are also examined by immunofluorescent staining using nucleolin antibody under appropriate for staining either intracellular or cell surface proteins.
- GRO29A 5'-FITC labeled analog of GRO29A is used.
- Cells (initially DU145 and PC- 3) are treated with this ohgonucleotide delivered by a variety of different methods. These will include electroporation, cationic lipids (1 ⁇ g GRO29A: 4 ⁇ g DOTAP-DOPE [1:1]), polymyxin B sulfate (Sigma), lactic acid nanoparticles (a simple synthesis is described in Berton et al. (1999) Eur. J. Pharm. Biopharm.
- mice Male nude mice (nine in total) are subcutaneously (s.c.) inoculated by their hind flank with DU145 prostate cancer cells under mild anesthesia. When tumors are established (approximately 0.5 cm diameter), the mice are treated with a single 5 mg/kg dose of GRO29A (a mixture of labeled and unlabeled ohgonucleotide) in a volume of 25 ⁇ l by intratumoral, intraperitoneal or intravenous (tail vein) injection.
- GRO29A a mixture of labeled and unlabeled ohgonucleotide
- mice are euthanized by CO 2 inhalation, the tumor excised, and blood and organs are collected. Levels of radioactivity in the tumor, serum, liver, kidney, spleen and prostate are examined. Stability is determined by denaturing PAGE of serum samples. Similar experiments are also carried out using the Dunning prostatic carcinoma model. Isaacs et al. (1978) Cancer Res. 38(11 Pt 2):4353-9; Zaccheo et al. (1998) Prostate 35(4):237-42. If any of the delivery techniques tested in cultured cells result in significantly improved uptake (and are appropriate for in vivo delivery), they are also tested. These experiments determine the optimal administration routes in rats and mice, and provide an indication of the optimal dosing schedule. All animal experiments strictly adhere to institutional guidelines on animal care and use.
- mice are inoculated s.c. with DU145 cells under mild anesthesia. After the establishment of palpable xenografts, mice are treated (six mice per group) with GRO29A, control ohgonucleotide (5'-GACTGTACCGAGGTGCAAG
- Three treatment groups receive 0.5, 5 or
- mice 50 mg/kg doses twice per week for two weeks. Body weight and tumor size (measured with calipers) are monitored. At an appropriate time, the mice are euthanized by inhalation of CO and tumors excised. Sections of the tumor are examined by morphological analysis and immunostaining, including nucleolin, PCNA, Ki 67 and TUNEL analysis for apoptosis. Similar experiments using the optimal (or economically feasible) dose are carried to determine efficacy of GRO29A in inhibiting PC-3 and LNCaP xenografts. Models of metastatic prostate cancer are then implemented. Surgical orthotopic implantation of PC- 3 tumors to the prostate glands of nude mice has been reported recently (An et al.
- This group comprises agents with diverse mechanisms of action, e.g. topoisomerase
- I and II inhibitors mitosis inhibitors, and DNA damaging agents.
- the activity of these are tested in cultured cells using the MTT assay to determine cell number.
- Cells are treated by addition of drug (at the GI 30 dose) to the medium, followed twenty- four hours later by addition of GRO29A (GI 30 dose), or in the reverse sequence.
- GRO29A GI 30 dose
- cells are examined for cell cycle perturbation (by flow cytometry) and apoptosis (flow cytometry of annexin V-stained cells). Synergistic combinations are also tested in vivo, as described above.
- Nucleolin Inhibitors Small molecule inhibitors of nucleolin may be more practical alternatives to oligonucleotides.
- Homology modeling (with MSI Modeller and Homology programs) is used to build a 3D model of nucleolin from its sequence alignment with known structures of related proteins (16 have been identified). Standard techniques of backbone building, loop modeling, structural overlay and statistical analysis of the resulting models are used. The homology model will be refined using molecular dynamics.
- the virtual screen uses the MSI Ludi software combined with the ACD database.
- Ludi fits molecules into the active site of nucleolin by matching complementary polar and hydrophobic groups. An empirical scoring function is used to prioritize the hits. Ludi also suggests modifications that may increase the binding affinity between the active oligonucleotides and nucleolin, and can also improve the homology model of nucleolin by inference from the binding of the active oligonucleotides.
- the ACD structural database contains
- G-rich Oligonucleotides The effects of four G-rich phosphodiester oligonucleotides (GROs) on the growth of tumor cells in culture were tested. These oligonucleotides consisted entirely of deoxyguanosine and thymidine and contained at least two contiguous guanosines. For increased stability to serum nucleases, oligonucleotides were modified at the 3 '-terminus with a propylamino group. This modification
- Figure 1A-D shows the results of MTT assays for determining relative numbers of viable cells in treated cell lines derived from prostate (DU145), breast (MDA-MB-231, MCF-7) or cervical (HeLa) carcinomas.
- GRO29A and GRO 15 A Two oligonucleotides, GRO29A and GRO 15 A, consistently inhibited proliferation in all of the cell lines tested.
- GR029A had a more potent inhibitory effect than GRO15A (for MCF-7 cells, the oligonucleotides had similar effects).
- GRO29A has a lesser growth inhibitory effect on a non-malignant cell line (HS27) compared to most malignant cell lines, for example, DU145, MDA-MG-231. Also, GRO29A has antiproliferative effects against leukemia cell lines, for example, K562 and U937, as shown in Figure 3. It has a lesser growth inhibitory effect against a non-malignant hematopoietic stem cell line (ATCC 2037).
- G-quartet Formation by G-rich Oligonucleotides To investigate the formation of G-quartet structures by the G-rich oligonucleotides, a UN. melting technique described by Mergny et al. (1998) EEES Eett. 435, 74-78 was used. This method relies on the fact that dissociation of G-quartets leads to a decrease in absorbance at 295 nm and is reported to give a more reliable indication of intramolecular G-quartet formation than measurement at 260 nm. As a control for G-quartet formation, we used a single-stranded ohgonucleotide, T ⁇ L.
- This ohgonucleotide contains four repeats of the human telomere sequence 5 '-TTAGGG and is known to form a G-quartet structure in vitro.
- Figure 4A shows the annealing curve for this sequence. G-quartet formation is indicated by a clear transition with a melting temperature of 66°C. The transition was reversible and a slight hysteresis was observed between heating and cooling curves (not shown) at
- oligonucleotides was assessed. Although this method may underestimate absolute cellular uptake of ohgonucleotide due to the action of phosphomonoesterase in removing the 5 '-label, it can provide useful
- Figure 5 shows the relative uptake of oligonucleotides into cells after ten hours, as measured by cell-associated radioactivity.
- the order of uptake i.e. GRO15A > GRO29A ⁇ CRO > GRO15B > GRO26A > MIX1 was the same at twenty-six hours. The presence of intact ohgonucleotide inside cells was verified by polyacrylamide electrophoresis of cell lysates.
- oligonucleotides were incubated with HeLa nuclear extracts, alone or in the presence of unlabeled competitor ohgonucleotide, and examined by an electrophoretic mobility shift assay.
- the G-quartet forming telomere sequence ohgonucleotide, TEL was included as a competitor in this experiment.
- a single stranded ohgonucleotide, TEL was also included as a competitor in this experiment.
- TEL contains four repeats of the human telomere sequence 5'-
- TTAGGG-3' is known to form a G-quartet structure in vitro.
- Figure 6A shows the formation of a stable protein-oligonucleotide complex (marked "*"). This band was intense when the labeled ohgonucleotide was one of the growth inhibitory oligonucleotides, GRO15A or GRO29A (lanes 1 and 5), but the inactive ohgonucleotide, GRO26A, formed only a weak complex (lane 9). This experiment also showed that the complex could be effectively competed by either unlabeled antiproliferative ohgonucleotide or TEL, but not by the inactive GRO26A.
- the molecular weight of the nuclear protein was more accurately determined by Southwestern blotting.
- HeLa nuclear extracts were electrophoresed on an 8% polyacrylamide-SDS gel and transferred to a PNDF membrane. The membrane was blocked and cut into strips. Each strip was incubated at 4°C with a 32 P-labeled G-rich ohgonucleotide in the presence of unrelated unlabeled double stranded and single stranded D ⁇ A to block nonspecific binding.
- Figure 6D shows active oligonucleotides GRO15A and GRO29A hybridized to a single protein band at 106 kDa (the band was exactly adjacent to a 106 kDa molecular mass marker, not shown).
- GRO14A, GRO25A, GRO28A Three of the new oligonucleotides (GRO14A, GRO25A, GRO28A) displayed a moderate antiproliferative activity but were not as potent as GRO29A.
- Ohgonucleotide GRO14B showed no antiproliferative activity.
- the moderate active oligonucleotides were able to compete with TEL for binding to the nuclear protein, though not as effectively as GRO29A.
- the non-inhibitory ohgonucleotide, GRO14B was unable to compete for protein binding.
- Non-G-rich Oligonucleotides Effects of Non-G-rich Oligonucleotides. To investigate the specificity of the antiproliferative effects, the growth inhibitory effects of non-G-rich oligonucleotides and heparin, a polyanionic polysaccharide, were examined.
- Figure 7C shows that at 10 ⁇ M concentration (equivalent to approximately 0.1 mg/ml for GRO29A), neither a 3 '-modified C-rich ohgonucleotide (CRO) nor
- MIX1 mixed base ohgonucleotide
- Heparin also had no effect on cell growth when added to the culture medium at a concentration of 20 units/ml (approximately 0.12 mg/ml), further demonstrating that the antiproliferative effects of active oligonucleotides are not simply a result of their polyanionic character.
- a slightly modified treatment protocol was used in
- MIX1 was anomalous. Although this ohgonucleotide had no effect on the growth of cells, it appeared to compete for protein binding in the competitive EMSA.
- nucleolin was tested. Nuclear extracts from HeLa cells (purchased from Promega) or MDA-MG-231 breast cancer cells (obtained in Applicants laboratory by standard procedures) were electrophoresed and transferred to PNDF membrane. The immobilized proteins were probed for binding to 32 P- labeled GRO15A using the Southeastern procedure described, and visualized by overnight exposure to autoradiographic film. The same membrane was stripped of ohgonucleotide by the denaturation/renaturation steps described (Experimental Procedures, see "Southwestern Blotting") and Western-blotted using nucleolin antiserum as primary antibody and a horseradish peroxidase (HRP) conjugated anti-rabbit secondary antibody.
- HRP horseradish peroxidase
- the blot was visualized by incubation with a chemiluminescence detection reagent followed by a twenty second exposure to autoradiographic film.
- the results are shown in Figure 9A.
- Southwestern blots of nuclear extracts showed an intense band upon hybridization and radiolabeled GRO 15 A, at 106 kDa (HeLa) or approximately 116 kDa (MDA-MB-231).
- the Western blot of MDA-MB-231 nuclear proteins shows one intense band at approximately 116 kDa and weaker bands at about 50 kDa.
- the nucleolin antibody recognizes multiple bands at approximately 50, 75, 106 and 120 kDa.
- nucleolin is a protein that can be phosphorylated in cells by a number of kinases, and is also susceptible to self-proteolysis. Zhou et al. (1997) J. Biol. Chem. 272, 31130-31137; Schwab et al. (1997) Eur. J. Cell Biol. 73, 287-297; Li et al. (1996) J Biol. Chem. 271, 15662-15668; Peter et al. (1990) Cell 60, 791-801; Belenguer et al. (1990) Mol. Cell Biol.
- biotinylated G-rich oligonucleotides were used to treat binding of the specific protein occurred within the cell environment.
- nucleolin GRO-binding protein in the antiproliferative activity of GRO was shown as the sensitivity of cell lines to GRO effects was found to be related to levels of GRO binding protein (detected by Southwestern blotting of cell extracts). For example, cell lines which are most sensitive to GRO effects (DE145, MDA-MB-231, HeLa) had high levels of pi 10, whereas less sensitive cell lines (HS27, MCF-7) or resistant cell lines (a methotrexate-resistant MCF-7 derivative) had low or undetectable levels of pi 10. Additionally, nucleolin levels were found to be significantly altered by GRO-treated cells and untreated cells in exponential growth as shown in Figure 9 wherein an overall increase in immunofluorescence was found for treated (B) vs. untreated (A) MDA-MB- 231 cells seventy-two hours following GRO29A treatment using anti-nucleolin staining and a translocation to the cytoplasm was also observed. The TEL-protein complex is competed for most effectively by
- GRO29A and OMR29A (lanes 2 and 13), which are two potent antiproliferative oligonucleotides.
- the complex is not competed for, or is competed to a lesser extent, by compounds with no antiproliferative activity (e.g. caffeine, polymyxin or heparin) or by commonly used therapeutic agents whose mechanisms are known to result from properties other than nucleolin binding (e.g. 5-FU, taxol or cis-platin).
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60036700T DE60036700T2 (en) | 1999-04-08 | 2000-04-07 | ANTIPROLIFERATIVE ACTIVITY OF G-rich OLIGONUCLEOTIDES AND METHOD TO USE THEM TO BIND NUCLEOTINE |
AU42129/00A AU775412B2 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
EP00921868A EP1181304B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
CA002370000A CA2370000A1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
JP2000610866A JP2002541264A (en) | 1999-04-08 | 2000-04-07 | Anti-proliferative activity of G-rich oligonucleotide and its use for binding to nucleolin |
US09/958,251 US7314926B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
DK00921868T DK1181304T3 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative effect of G-rich oligonucleotides and method of using them to bind nucleolin |
US10/978,032 US8648051B2 (en) | 1999-04-08 | 2004-10-29 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,451 US20080318890A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,446 US20080318889A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,427 US7960540B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,413 US8114850B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,364 US20110178161A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12831699P | 1999-04-08 | 1999-04-08 | |
US14982399P | 1999-08-19 | 1999-08-19 | |
US60/149,823 | 1999-08-19 | ||
US60/128,316 | 1999-08-19 |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/958,251 A-371-Of-International US7314926B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
US10/978,032 Division US8648051B2 (en) | 1999-04-08 | 2004-10-29 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,364 Continuation-In-Part US20110178161A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,413 Continuation-In-Part US8114850B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,451 Continuation-In-Part US20080318890A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,446 Continuation-In-Part US20080318889A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,427 Continuation-In-Part US7960540B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000061597A1 WO2000061597A1 (en) | 2000-10-19 |
WO2000061597A9 true WO2000061597A9 (en) | 2001-11-29 |
Family
ID=26826478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/009311 WO2000061597A1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
Country Status (12)
Country | Link |
---|---|
US (2) | US7314926B1 (en) |
EP (1) | EP1181304B1 (en) |
JP (1) | JP2002541264A (en) |
AT (1) | ATE375358T1 (en) |
AU (1) | AU775412B2 (en) |
CA (1) | CA2370000A1 (en) |
CY (1) | CY1106991T1 (en) |
DE (1) | DE60036700T2 (en) |
DK (1) | DK1181304T3 (en) |
ES (1) | ES2296615T3 (en) |
PT (1) | PT1181304E (en) |
WO (1) | WO2000061597A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104703608A (en) * | 2012-02-16 | 2015-06-10 | 多伦多大学理事会 | Guanosine-rich oligonucleotide (GRO) compostions, methods and uses for treating respiratory syncytial virus infection |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541264A (en) | 1999-04-08 | 2002-12-03 | ユーエイビー・リサーチ・ファウンデーション | Anti-proliferative activity of G-rich oligonucleotide and its use for binding to nucleolin |
US20110178161A1 (en) * | 1999-04-08 | 2011-07-21 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7544767B2 (en) * | 2002-04-05 | 2009-06-09 | Burnham Institute For Medical Research | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US20050187176A1 (en) * | 2003-10-10 | 2005-08-25 | Bates Paula J. | Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases |
FR2900341B1 (en) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR THE TREATMENT OF CANCER |
US8481529B2 (en) | 2006-05-16 | 2013-07-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
EP2268284A2 (en) * | 2008-02-05 | 2011-01-05 | Antisoma Research Limited | Use of g-rich oligonucleotides for treating neoplastic diseases |
GB2460086A (en) * | 2008-05-16 | 2009-11-18 | Antisoma Res Ltd | Treatment of paediatric cancers |
BRPI0822661A2 (en) | 2008-05-22 | 2015-06-30 | Centre Nat Rech Scient | Optically pure compounds for improved therapeutic efficiency |
WO2010030849A1 (en) * | 2008-09-12 | 2010-03-18 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death |
KR100998365B1 (en) * | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof |
CN102770529B (en) | 2009-11-17 | 2018-06-05 | Musc研究发展基金会 | For the human monoclonal antibodies of people's paranuclein |
US20130065227A1 (en) * | 2010-03-04 | 2013-03-14 | Paula J. Bates | Methods of increasing macropinocytosis in cancer cells |
WO2011133142A1 (en) * | 2010-04-20 | 2011-10-27 | University Of Louisville | Treatment of vhl-negative tumors |
AU2011311665A1 (en) | 2010-10-04 | 2013-05-02 | Centre National De La Recherche Scientifique (Cnrs) | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
ES2880291T3 (en) | 2011-06-02 | 2021-11-24 | Univ Louisville Res Found Inc | Nanoparticles conjugated to an antinucleolin agent |
JP6155533B2 (en) * | 2012-02-28 | 2017-07-05 | 国立大学法人東京農工大学 | Identification method for TDP-43 intracellular abundance-related diseases |
CN104661664B (en) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | Chiral control |
EP2982756A1 (en) * | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
CA3009378A1 (en) * | 2015-12-23 | 2017-06-29 | Queensland University Of Technology | Nucleic acid oligomers and uses therefor |
CN114807152A (en) | 2016-06-08 | 2022-07-29 | 哈佛学院院长及董事 | Engineered viral vectors reduce induction of inflammation and immune responses |
EP3493852A1 (en) | 2016-08-02 | 2019-06-12 | University of Louisville Research Foundation, Inc. | Targeted nanodroplet emulsions for treating cancer |
KR20190065139A (en) | 2017-12-01 | 2019-06-11 | 압타바이오 주식회사 | Therapeutics of blood cancer |
WO2021234550A1 (en) | 2020-05-19 | 2021-11-25 | 애니젠 주식회사 | Novel nucleolin-binding peptide and use thereof |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US5705334A (en) | 1988-09-22 | 1998-01-06 | Massachusetts Institute Of Technology | Uses for DNA structure-specific recognition protein |
US5359047A (en) | 1988-09-22 | 1994-10-25 | Massachusetts Institute Of Technology | Nucleic acids encoding DNA structure-specific recognition protein and uses therefor |
US5495070A (en) | 1988-10-04 | 1996-02-27 | Agracetus, Inc. | Genetically engineering cotton plants for altered fiber |
CA2006008C (en) * | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5714575A (en) | 1989-02-13 | 1998-02-03 | The University Of Medicine And Dentistry Of New Jersey | Nucleic acids sequence, stress-induced proteins and uses thereof |
US5561222A (en) | 1989-11-15 | 1996-10-01 | Duke University | RNA-binding proteins useful for the control of cellular genetic processing and expression |
US5212058A (en) | 1990-05-09 | 1993-05-18 | Massachusetts Institute Of Technology | Nucleic acid encoding ubiquitin-specific proteases |
DE4021571A1 (en) | 1990-07-06 | 1992-01-16 | Boehringer Mannheim Gmbh | N-METHYLHYDANTOINASE, CLONED |
US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
US5310892A (en) | 1990-12-10 | 1994-05-10 | The Rockefeller University | Nucleic acid sequence which codes for and expresses human fibrillarin and uses thereof |
US5470971A (en) | 1991-03-11 | 1995-11-28 | The University Of Medicine And Dentistry Of New Jersey | Stress-induced proteins, genes coding therefor, transformed cells of organisms, methods and applications |
US5612201A (en) | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5925729A (en) | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US5624818A (en) | 1991-09-09 | 1997-04-29 | Fred Hutchinson Cancer Research Center | Nucleic acids encoding regulatory proteins that dimerize with Mad or Max |
US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
US5376546A (en) | 1991-11-04 | 1994-12-27 | Xoma Corporation | Analogs of ribosome-inactivating proteins |
US5688511A (en) | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
US6153408A (en) | 1991-11-15 | 2000-11-28 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
US5499967A (en) * | 1992-02-27 | 1996-03-19 | Societe Anonyme Dite: Laboratoires D'hygiene Societe Anonyme Dite: Et De Dietetique (L.H.D.) | Transdermal drug delivery device with waveshape generator |
US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6235313B1 (en) * | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5444149A (en) | 1992-05-11 | 1995-08-22 | Duke University | Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation |
US5686306A (en) | 1992-05-13 | 1997-11-11 | Board Of Regents, The University Of Texas System | Methods and reagents for lengthening telomeres |
US5645986A (en) | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5489508A (en) * | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6323185B1 (en) * | 1993-04-23 | 2001-11-27 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-viral guanosine-rich oligonucleotides and method of treating HIV |
US6288042B1 (en) | 1993-04-23 | 2001-09-11 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich tetrad forming oligonucleotides |
US5443962A (en) | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US5804380A (en) | 1993-11-12 | 1998-09-08 | Geron Corporation | Telomerase activity assays |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5614503A (en) | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
US5449758A (en) | 1993-12-02 | 1995-09-12 | Life Technologies, Inc. | Protein size marker ladder |
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5763174A (en) | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
US5643778A (en) | 1994-02-17 | 1997-07-01 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US6183751B1 (en) * | 1994-08-18 | 2001-02-06 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's Sarcoma virus sequences and uses thereof |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
US5624799A (en) | 1995-02-13 | 1997-04-29 | The Burnham Institute | Cancer-associated mar binding protein |
US6020139A (en) | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
WO1996035126A1 (en) | 1995-05-03 | 1996-11-07 | President And Fellows Of Harvard College | Assessing calcineurin's role in immunosuppression and neurotoxicity |
US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
US5763178A (en) | 1995-06-07 | 1998-06-09 | Trevigen, Inc. | Oscillating signal amplifier for nucleic acid detection |
US5656430A (en) | 1995-06-07 | 1997-08-12 | Trevigen, Inc. | Oscillating signal amplifier for nucleic acid detection |
WO1997002279A1 (en) | 1995-07-06 | 1997-01-23 | Ctrc Research Foundation | Methods and compositions for modulation and inhibition of telomerase |
US5968506A (en) * | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
US5783398A (en) | 1995-09-15 | 1998-07-21 | Merck & Co., Inc. | High throughput assay using fusion proteins |
US5776696A (en) | 1995-09-15 | 1998-07-07 | Merck & Co., Inc. | High throughput assay using fusion proteins |
US5854223A (en) | 1995-10-06 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | S-DC28 as an antirestenosis agent after balloon injury |
US5861498A (en) | 1995-11-01 | 1999-01-19 | Thomas Jefferson University | Nucleotides encoding immunophilin FKBP46 and fragments thereof |
JP3089350B2 (en) | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Inhibitors of cyclophilin rotamase activity |
US6214805B1 (en) * | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
DK0885002T3 (en) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materials and methods for enhancing cellular internalization |
US6030955A (en) | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
US6331617B1 (en) | 1996-03-21 | 2001-12-18 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
US6274313B1 (en) | 1996-03-21 | 2001-08-14 | Pioneer-Hybrid International, Inc. | Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use |
US5734040A (en) | 1996-03-21 | 1998-03-31 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
WO1997036005A1 (en) | 1996-03-26 | 1997-10-02 | Lynx Therapeutics, Inc. | Oligonucleotide treatments and compositions for human melanoma |
CA2175435A1 (en) | 1996-04-30 | 1997-10-31 | Joseph Lam | Proteins involved in the synthesis and assembly of o-antigen in pseudomonas aeruginosa |
US6027881A (en) * | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US5756710A (en) | 1996-06-05 | 1998-05-26 | The Trustees Of Columbia University In City Of New York | Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof |
US5792613A (en) | 1996-06-12 | 1998-08-11 | The Curators Of The University Of Missouri | Method for obtaining RNA aptamers based on shape selection |
US5780447A (en) | 1996-06-14 | 1998-07-14 | St. Jude Children's Research Hospital | Recombinant adeno-associated viral vectors |
US6348586B1 (en) * | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
US6107029A (en) | 1996-07-31 | 2000-08-22 | Message Pharmaceticals, Inc. | Universal method for detecting interactions between RNA molecules and RNA binding proteins |
US5691145A (en) | 1996-08-27 | 1997-11-25 | Becton, Dickinson And Company | Detection of nucleic acids using G-quartets |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US5898860A (en) * | 1996-10-01 | 1999-04-27 | Leibold; William Steven | System and method for automatically generating a control drawing for a real-time process control system |
DE69723531T3 (en) | 1996-10-01 | 2012-09-06 | Geron Corp. | Catalytic subunit of human telomerase |
US5849564A (en) | 1996-11-29 | 1998-12-15 | The Trustees Of Columbia University In The City Of New York | Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof |
CA2276462C (en) | 1996-12-31 | 2007-06-12 | Genometrix Incorporated | Multiplexed molecular analysis system apparatus and method |
US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
FR2763943B1 (en) | 1997-05-28 | 1999-07-09 | Rhone Poulenc Rorer Sa | COMPOUNDS, THEIR PREPARATION AND THEIR USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS |
US6028058A (en) | 1997-07-21 | 2000-02-22 | Ciblex Corporation | Methods and compositions for regulating nuclear trafficking of proteins |
AU750947C (en) | 1997-09-22 | 2003-05-22 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid catalysts with endonuclease activity |
US6025194A (en) | 1997-11-19 | 2000-02-15 | Geron Corporation | Nucleic acid sequence of senescence asssociated gene |
US6455250B1 (en) | 1997-12-11 | 2002-09-24 | The Regents Of The University Of California | Endonuclease compositions and methods of use |
US5989860A (en) | 1997-12-12 | 1999-11-23 | Incyte Pharmaceuticals, Inc. | Human isomerase homologs |
US5932475A (en) | 1997-12-12 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human nucleolin-like protein |
US5989823A (en) | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US6376226B1 (en) * | 1998-01-09 | 2002-04-23 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
US6071732A (en) | 1998-01-29 | 2000-06-06 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferases, nucleic acids encoding tyrosylprotein sulfotransferases, and methods of use thereof |
US6255055B1 (en) * | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
US6332897B1 (en) | 1998-03-27 | 2001-12-25 | Glaxo Wellcome Inc. | Assay methods |
US6180348B1 (en) * | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
US6017709A (en) | 1998-04-29 | 2000-01-25 | University Of Houston | DNA replication templates stabilized by guanine quartets |
US6171843B1 (en) * | 1998-06-01 | 2001-01-09 | Incyte Pharmaceuticals, Inc. | Human peptidyl-prolyl isomerases |
US6274725B1 (en) | 1998-06-02 | 2001-08-14 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
JP4013333B2 (en) * | 1998-06-05 | 2007-11-28 | 株式会社B&Cラボラトリーズ | Method for measuring skin aging and measuring kit |
US6399302B1 (en) * | 1998-08-21 | 2002-06-04 | University Of Virginia Patent Foundation | Signal generating oligonucleotide-based biosensor |
EP1115737A4 (en) | 1998-09-23 | 2004-11-24 | Cleveland Clinic Foundation | Novel interferon stimulated and repressed genes |
US6465176B1 (en) | 1998-10-02 | 2002-10-15 | Message Pharmaceuticals, Inc. | Method for identifying compounds RNA/RNA binding protein interactions |
US6423493B1 (en) * | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
US6426231B1 (en) * | 1998-11-18 | 2002-07-30 | The Texas A&M University System | Analyte sensing mediated by adapter/carrier molecules |
US6177254B1 (en) * | 1998-12-15 | 2001-01-23 | Jerome Bernard Rattner | Nucleolus autoantigenic marker for systemic lupus erthyematosus |
US5948680A (en) | 1998-12-17 | 1999-09-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of Elk-1 expression |
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
MXPA01009888A (en) | 1999-03-29 | 2003-07-21 | Iaf Biochem Int | Methods of treating leukemia. |
US6383752B1 (en) * | 1999-03-31 | 2002-05-07 | Hybridon, Inc. | Pseudo-cyclic oligonucleobases |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
JP2002541264A (en) * | 1999-04-08 | 2002-12-03 | ユーエイビー・リサーチ・ファウンデーション | Anti-proliferative activity of G-rich oligonucleotide and its use for binding to nucleolin |
US20080318889A1 (en) | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20080318890A1 (en) | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
ATE233795T1 (en) * | 1999-04-23 | 2003-03-15 | Molecular Probes Inc | XANTHENE DYES AND THEIR APPLICATION AS LUMINESCENCE-CANCELING COMPOUNDS |
US6316200B1 (en) | 2000-06-08 | 2001-11-13 | Becton, Dickinson And Company | Probes and methods for detection of nucleic acids |
US6200746B1 (en) * | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US6379888B1 (en) * | 1999-09-27 | 2002-04-30 | Becton, Dickinson And Company | Universal probes and methods for detection of nucleic acids |
US6420122B1 (en) * | 1999-09-27 | 2002-07-16 | Massachusetts Institute Of Technology | Methods of screening for agents that inhibit aggregation of polypeptides |
US6165789A (en) | 1999-10-27 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of hnRNP A1 expression |
US6165786A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of nucleolin expression |
DE60036019T2 (en) | 1999-12-13 | 2008-05-29 | Bioniche Life Sciences Inc., Belleville | SYNTHETIC OLIGONUCLEOTIDES THAT ARE THERAPEUTICALLY USEFUL |
US6291187B1 (en) | 2000-05-12 | 2001-09-18 | Molecular Staging, Inc. | Poly-primed amplification of nucleic acid sequences |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
JP2005530515A (en) | 2002-06-26 | 2005-10-13 | ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド | Apoptosis detection method |
US20050187176A1 (en) | 2003-10-10 | 2005-08-25 | Bates Paula J. | Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases |
US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
EP2268284A2 (en) | 2008-02-05 | 2011-01-05 | Antisoma Research Limited | Use of g-rich oligonucleotides for treating neoplastic diseases |
-
2000
- 2000-04-07 JP JP2000610866A patent/JP2002541264A/en not_active Ceased
- 2000-04-07 PT PT00921868T patent/PT1181304E/en unknown
- 2000-04-07 US US09/958,251 patent/US7314926B1/en not_active Expired - Lifetime
- 2000-04-07 AT AT00921868T patent/ATE375358T1/en not_active IP Right Cessation
- 2000-04-07 EP EP00921868A patent/EP1181304B1/en not_active Expired - Lifetime
- 2000-04-07 DE DE60036700T patent/DE60036700T2/en not_active Expired - Lifetime
- 2000-04-07 DK DK00921868T patent/DK1181304T3/en active
- 2000-04-07 AU AU42129/00A patent/AU775412B2/en not_active Ceased
- 2000-04-07 WO PCT/US2000/009311 patent/WO2000061597A1/en active IP Right Grant
- 2000-04-07 ES ES00921868T patent/ES2296615T3/en not_active Expired - Lifetime
- 2000-04-07 CA CA002370000A patent/CA2370000A1/en not_active Abandoned
-
2004
- 2004-10-29 US US10/978,032 patent/US8648051B2/en not_active Expired - Lifetime
-
2007
- 2007-11-08 CY CY20071101441T patent/CY1106991T1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104703608A (en) * | 2012-02-16 | 2015-06-10 | 多伦多大学理事会 | Guanosine-rich oligonucleotide (GRO) compostions, methods and uses for treating respiratory syncytial virus infection |
Also Published As
Publication number | Publication date |
---|---|
WO2000061597A1 (en) | 2000-10-19 |
EP1181304A1 (en) | 2002-02-27 |
DE60036700D1 (en) | 2007-11-22 |
DK1181304T3 (en) | 2008-02-11 |
CY1106991T1 (en) | 2012-09-26 |
US7314926B1 (en) | 2008-01-01 |
CA2370000A1 (en) | 2000-10-19 |
AU775412B2 (en) | 2004-07-29 |
ES2296615T3 (en) | 2008-05-01 |
AU4212900A (en) | 2000-11-14 |
PT1181304E (en) | 2008-01-23 |
ATE375358T1 (en) | 2007-10-15 |
US20090326047A1 (en) | 2009-12-31 |
JP2002541264A (en) | 2002-12-03 |
EP1181304A4 (en) | 2002-10-02 |
EP1181304B1 (en) | 2007-10-10 |
US8648051B2 (en) | 2014-02-11 |
DE60036700T2 (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7314926B1 (en) | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin | |
Crooke | Antisense therapeutics | |
US6369038B1 (en) | Closed antisense and sense oligonucleotides and their applications | |
JP3054745B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
US20020039741A1 (en) | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | |
US8114850B2 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
US7893242B2 (en) | Oligonucleotide compositions and their use to induce apoptosis | |
JPH09507502A (en) | Antisense oligonucleotide regulation of raf gene expression | |
Ma et al. | Synthetic oligonucleotides as therapeutics: the coming of age | |
US6001991A (en) | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression | |
US7960540B2 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
US6080727A (en) | Oligonucleotide treatments and compositions for human melanoma | |
Jing et al. | Rational drug design of G-quartet DNA as anti-cancer agents | |
US20080318889A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
US20080318890A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
EP1432450B1 (en) | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides | |
EP1930340A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using the same to bind to nucleolin | |
US20110178161A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
AU2002341264A1 (en) | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides | |
CA2743828C (en) | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells | |
Geiger et al. | antisense oligonucleotides, mdm2, p53, apoptosis | |
US7528117B2 (en) | High efficacy antisense RIαPKA poly-DNP oligoribonucleotides | |
WO2023192828A2 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
Tidd et al. | Mechanisms of action of antisense oligonucleotides | |
Stewart | The efficacy of clamp-forming antisense oligonucleotides on c-myc oncogene expression in a mouse melanoma model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2370000 Country of ref document: CA Ref country code: CA Ref document number: 2370000 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 610866 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000921868 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09958251 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000921868 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000921868 Country of ref document: EP |